R. Schreck

发表

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Juthamas Sukbuntherng, Robert A Blake, Guangmin Li, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.

G. Mcmahon, L. Sun, C. Tang, 1999, Journal of medicinal chemistry.

Authentic 17kDa tumour necrosis factor α is synthesized and released by canine mast cells and up‐regulated by stem cell factor

S. Lazarus, P. Thomas, R. Schreck, 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Daclizumab in vitro inhibits the secretion of pro-asthmatic and pro-inflammatory cytokines by activated T cells

J. Sheridan, T. Tsao, V. Vexler, 2005 .

Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.

S. Hubbard, G. Mcmahon, L. Sun, 2000, Journal of medicinal chemistry.

Growth factor production by human thyroid carcinoma cells: abundant expression of a platelet-derived growth factor-B-like protein by a human papillary carcinoma cell line.

S. Rubin, J. Fagin, K. Matsuo, 1993, The Journal of clinical endocrinology and metabolism.

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

A. Ullrich, G. Mcmahon, L. Sun, 1999, Cancer research.

Heparin inhibits histamine release from canine mast cells.

S. Lazarus, N. Inase, R. Schreck, 1993, The American journal of physiology.

Flk-1 as a target for tumor growth inhibition.

A. Ullrich, G. Kéri, G. Mcmahon, 1996, Cancer research.

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

J. Christensen, J. Cui, J. Cherrington, 2003, Cancer research.

Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines.

J. Köhrle, C. Schmutzler, R. Schreck, 1994, The Journal of clinical endocrinology and metabolism.

The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.

J. Cherrington, S. Vasile, D. Mendel, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

of Multiple Tumor Types Tyrosine Kinase Catalysis , Tumor Vascularization , and Growth Endothelial Growth Factor Receptor ( Flk-1 / KDR ) That Inhibits SU 5416 Is a Potent and Selective Inhibitor of the Vascular

A. Ullrich, G. Mcmahon, W. Risau, 1998 .

A tumor-derived protein which provides T-cell costimulation through accessory cell activation.

A. Ullrich, H. App, M. Azam, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.

J. Christensen, J. Cherrington, E. Chan, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Heterogeneity of intact granules purified from canine mastocytoma cell lines.

S. Lazarus, S. Ruoss, P. Thomas, 1991, American Journal of Physiology.

Tobacco smoke releases performed mediators from canine mast cells and modulates prostaglandin production.

S. Lazarus, P. Thomas, R. Schreck, 1992, The American journal of physiology.

Prostaglandin D2 production and identification of prostaglandin H synthase within canine mast cell granule.

S. Lazarus, P. Thomas, R. Schreck, 1992, American Journal of Physiology.

A phase I dose-escalation study of the polo-like kinase 1 inhibitor volasertib (BI 6727) with two different dosing schedules in patients with advanced solid malignancies.

T. Taube, W. Su, H. Fritsch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.